« Back
Home /
Partner: Genorise|Hölzel Diagnostika | exclusive

Genorise Scientific

GENORISE SCIENTIFIC, INC. is a biomarker technology company founded in 2009, with commitment to disease diagnostics and drug discovery and is located in great Philadelphia area (USA). The company seeks novel biomarkers and develops novel reagents and instruments for specific detections of biomolecules and provides bioanalytical testing services. The company develops nanotechnology to reach its goal for more efficient detection methods and drug delivery. Their mission is to help reach your goal in research and product development and to provide reliable and affordable reagents and services that are important to today’s market and limited funds. Their goal is to provide the laboratory inexpensive quality reagents that produce reproducible results and to provide the inexpensive quality services that are accredited and highly recognized in the field. Their customers are from 52 countries covering North America, Europe, Asia, South America and Africa in various biomedical fields and are from universities, hospitals, biotech/pharmaceutical industries and medical instrument companies. Number of their customers reached 320 in May, 2017. GENORISE SCIENTIFIC, INC. product citations increase more than 100% each year and many of their products have been cited in peer-reviewed publications including “Nature”, “Stem Cell Research and Therapy”, and “PLOS ONE”.

GENORISE SCIENTIFIC, INC. offers quality reagents with affordable prices. These reagents cover ELISA kits, DNA/RNA kits, antibody, recombinant proteins, bio conjugates and multiplex bioassay kit. They also offer reliable biological testing services such as ELISA assays, genetic tests, forensic testing, genetic engineering, and molecular diagnosis of medical conditions. GENORISE SCIENTIFIC, INC. challenges today's market to provide cost-effective products to meet your demand. With many years of experience, they assure you with their reliable products that lead you to success. GENORISE SCIENTIFIC, INC. Scientific also serves as a CRO company that provides various services including gene knockout animal models. They have excellent experience in gene-editing in vivo that has been widely used in biomedical research, new disease discovery and new drug development. One of their goals is to discover novel disease biomarkers that can significantly benefit early detection of diseases and development of more effective therapeutic drugs. With proven technology, the company is leading to succeed in identification of unknown biomarkers for diseases like myocardial infarction and cancer. Multiple biomarkers provide better prediction of disease status and medical intervention in contrast to single marker. Toward this, GENORISE SCIENTIFIC, INC. is making effort to define and validate multiple disease biomarkers and to develop a multiplexed detection platform for rapid screening and early diagnosis of diseases using advanced technology such as lab-on-a-chip technology. Nanotechnology has proven beneficial to molecular diagnosis and drug delivery. The company is utilizing this cutting edge technology to develop novel molecular diagnostic methods and to develop nanomaterials for effective and safe drug delivery. The company is developing a strong product development team with expertise covering biomedicine, immunology, bioengineering and cell/molecular biology. With effective development of its marketing and sales team, the company is leading to achieve its mission.